Sweden. She holds a Masters in Pharmaceutical Sciences and a PhD from Uppsala University. Her research focuses on pharmacometrics and development of population pharmacokinetic and pharmacodynamic models for desired effects and adverse events in a range of therapeutic areas, such as oncology, bacterial infections, schizophrenia, rheumatoid arthritis, and QT prolongation. Currently, most of her research is focused on development of PKPD-models for quantitative, longitudinal predictions of use for

more »

... translation of drug effects from preclinical (in vitro and in vivo) to patients and from early to late clinical development. . He runs a modeling and simulation lab within the School of Pharmacy. Research interests include optimal design, MCMC methods particularly in clinical toxicology and haemostasis. He has been involved in the area of PKPD and nonlinear mixed effects modeling for 20 years. Currently his research involves the development of pharmacological models, modeling of data and the design of clinical studies. These foci essentially revolve around the therapeutic areas of coagulation, malaria and clinical toxicology. received the IEEE Engineering in Medicine and Biology Early Career Achievement Award. His previous research focus was on the development of data analysis software and the application of modeling and simulation to glucose and insulin metabolism, cancer, pharmacokinetics and pharmacodynamics. Since his move to Pfizer in 2008, his work has focused on translational modeling and simulation in support of various discovery programs. He has published more than 100 articles employing diverse modeling and simulation technology on a variety of applications. Ping Zhao, PhD Ping Zhao is currently the Scientific Lead of PBPK (physiologically-based pharmacokinetic modeling) Program in the Division of Pharmacometrics, Office of Clinical Pharmacology at US Food and Drug Administration. He is responsible for assessing PBPK analyses in IND and NDA submissions. Ping s research focuses on understanding the effect of intrinsic and/or extrinsic patient factors on drug exposure-response using PBPK models. Prior to 2008, he worked as a clinical pharmacologist